Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report sent to investors on Friday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright cut their price objective on Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th.

Minerva Neurosciences Stock Down 0.8 %

NASDAQ:NERV opened at $2.44 on Friday. Minerva Neurosciences has a twelve month low of $2.26 and a twelve month high of $13.49. The business has a 50 day moving average price of $2.68 and a two-hundred day moving average price of $2.80. The company has a market cap of $17.05 million, a P/E ratio of -0.55 and a beta of 0.14.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.12). As a group, analysts anticipate that Minerva Neurosciences will post -2.26 earnings per share for the current fiscal year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.